scroll
LEARN MORE
Performance update for March, stocks that drove returns & our current positioning
Close
Wednesday 24th April – ASX200 +17pts, Silver Lake (SLR), Kogan (KGN) & CPI
Close
Market Matters Research Lead Shawn Hickman with David Koch
Close
Wednesday 24th April – DOW +263pts, SPI +27pts
Close
14 DAYS FREE ACCESS
Join Market Matters and get full access
to all our Opinion + Action
IHL $0.00
20 MINUTE DELAYED
ANALYSIS
OPINION
i
PERFORMANCE
i
| SHARE PRICE ACTIVITY | |
|---|---|
| Last (Price) | 0.00 |
| Change | 0.00 (0) |
| Bid / Ask | 0.00 - 0.00 |
| Volume | 0 |
| Turnover | 0 |
| Open | 0.00 |
| Day Range | 0.00 - 0.00 |
| VWAP | 0.00 |
| Prev Close | 0.00 |
| Last Trade |
i
| KEY INFORMATION | |
|---|---|
| Sector | |
| Shares Issued | |
| NTA/Share | 0.00 |
| Last Dividend | 0.00 |
| Dividend Ex Date | 0 |
| Dividend Pay Date | 0 |
i
| CURRENT () | |
|---|---|
| Revenue | |
| EBITDA | |
| Profit | |
| Earnings Per Share (EPS) | 0 |
| Dividend Per Share (DPS) | 0 |
| Yield % | 0.00 |
| Market Cap | 0 |
| Price to Earnings Ratio (P/E) | 0 |
i
TARGET PRICE FORECAST
i
| ESTIMATES () | |
|---|---|
| Revenue | 0.00 |
| EBITDA | 0.00 |
| Profit | 0.00 |
| Earnings Per Share (EPS) | 0.00 |
| Dividend Per Share (DPS) | 0.00 |
i
BROKER CONSENSUS RECOMMENDATION
BUY
SELL
Target Price
0.00
Lt Growth Rate
0.00
Recommendation ()
0.00
Business Summary
Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical development company. The Company is focused on developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of generalized anxiety disorder (GAD), obstructive sleep apnea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation, rheumatoid arthritis and inflammatory bowel disease. Its drug candidates include IHL-42X, IHL-216A and HL-675A. Its IHL-42X is a combination of acetazolamide and dronabinol for treatment of OSA. Its IHL-216A is a combination of isoflurane and cannabidiol (CBD) to prevent development of TBI/concussion. Its HL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. It is also investigating the use of psilocybin assisted psychotherapy to treat GAD.
Relevant suggested news and content from the site
Video
WATCH
Performance update for March, stocks that drove returns & our current positioning
Recorded Tuesday 9th April
Podcast
LISTEN
Wednesday 24th April – ASX200 +17pts, Silver Lake (SLR), Kogan (KGN) & CPI
Daily Podcast Direct from the Desk
Video
WATCH
Market Matters Research Lead Shawn Hickman with David Koch
Recorded Monday 25th March
Podcast
LISTEN
Wednesday 24th April – DOW +263pts, SPI +27pts
Daily Podcast Direct from the Desk
Only available to Members
Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing.
Click here
